Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp (NASDAQ: DRIO) is a leader in digital therapeutics, revolutionizing chronic condition management through data-driven health solutions. This news hub provides investors and healthcare professionals with essential updates on corporate milestones, clinical validations, and strategic partnerships.
Access timely press releases covering earnings reports, product innovations, and business expansions. Our curated collection includes updates on Dario's integrated platform developments, partnership announcements with healthcare providers, and regulatory milestones in digital health.
Key focus areas include advancements in personalized coaching technologies, behavioral health integrations, and outcomes from clinical studies. Stay informed about DarioHealth's progress in merging life sciences with digital tools to improve chronic care management for employers, payers, and patients.
Bookmark this page for direct access to verified corporate communications. Check regularly for updates on DRIO's market-moving developments in the rapidly evolving digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) recently launched Dario Move, a new digital physical therapy solution aimed at managing musculoskeletal (MSK) conditions. This innovative product was presented at HLTH 2021 in Boston. The solution integrates advanced sensor technologies to provide personalized exercise programs and real-time coaching, enhancing accessibility to treatment. With 50% of U.S. adults affected by MSK disorders, Dario Move aims to reduce care costs and improve patient engagement. The company highlights the growing need for such digital therapies in an increasingly expensive healthcare landscape.
DarioHealth Corp. (Nasdaq: DRIO) has entered an agreement with a major U.S. national health plan to provide its digital behavioral health solution to self-insured employers. Initial member access is expected in Q4 2021, with wider rollout in 2022. Dario will earn a monthly fee for each member. This partnership aims to enhance mental health care access and improve member experience through AI-driven personalized care options. The agreement could generate millions in annual revenue and signifies potential for further opportunities with this client.
DarioHealth Corp. (Nasdaq: DRIO) will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The management's presentation is scheduled for Thursday, September 30, 2021, at 8:40 AM ET. Interested parties can register for the live webcast here. DarioHealth is recognized for its digital therapeutic solutions that enhance chronic condition management.
DarioHealth Corp. (Nasdaq: DRIO) announces that Chief Medical Officer, Dr. Omar Manejwala, will present at the American Health Insurance Plans' National Conference on Medicare, Medicaid, and Dual Eligibles on September 22, 2021, at 12:45 p.m. EST. His presentation will focus on the role of digital therapeutics in addressing health disparities among Medicaid populations. Dr. Manejwala emphasizes the need for tailored digital solutions to improve access and health outcomes for underserved groups, highlighting significant growth in digital health during the pandemic.
DarioHealth Corp. (Nasdaq: DRIO) has been selected by PeopleOne Health as its preferred digital behavioral health solution starting September 2021. This partnership aims to enhance mental health support for patients through AI-driven assessments and integrated digital tools. Rick Anderson, President of North America at DarioHealth, emphasized the importance of modern solutions for patient care, highlighting this agreement's validation of Dario's value in point-of-care settings. The collaboration underscores Dario's expansion in the provider market and its commitment to holistic health management.
DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q2 2021, with revenues of $5.3 million, growing 46% sequentially and 194% year-over-year. The company expanded its digital therapeutics offerings through acquisitions, enhancing its sales pipeline to over $900 million. Gross profit margins improved to 49.4%, reflecting growth in their SaaS model. However, the operating loss increased to $18 million, a 337% rise from the previous year. Cash reserves stood at $63.9 million, positioning Dario for ongoing growth amid increased operating expenses.
DarioHealth Corp. (Nasdaq: DRIO) announced a study at the ADCES conference showcasing the effectiveness of its personalized digital therapeutics platform. The research involved 3,609 members with Type 2 diabetes, showing a 19% reduction in high blood glucose readings compared to the control group. A notable 42% reduction was observed in non-insulin users. This study emphasizes the importance of real-time personalized interventions in influencing positive lifestyle changes and improving clinical outcomes.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
